Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of...
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15...
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell...
Nektar Therapeutics (Nasdaq: NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio...
Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team: Jonathan Zalevsky, Ph.D. has been promoted to ...
Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with...
Nektar Therapeutics (Nasdaq: NKTR) today announced that new data from a cohort of patients with metastatic triple-negative breast cancer who were...
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2019. Cash and investments in...
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 8, 2019, after the close of...
Nektar Therapeutics (Nasdaq: NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a...
Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company...
Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of...
Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused...
Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55th Annual Meeting of the American Society of...
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019. Cash and investments in...
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019, after the close of...
Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or...
Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen...
Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen...
Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2...
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018. Cash and...
Nektar Therapeutics (Nasdaq: NKTR) today announced several preclinical data presentations for its immuno-oncology pipeline candidates,...
Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL...
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2018, on Thursday, February ...
Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin1 (NKTR-214) in combination with...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.